NasdaqCM:CORT

Stock Analysis Report

Executive Summary

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Corcept Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.4%

NasdaqCM:CORT

-1.8%

US Pharmaceuticals

-1.0%

US Market


1 Year Return

-0.4%

NasdaqCM:CORT

-6.6%

US Pharmaceuticals

-0.4%

US Market

CORT outperformed the Pharmaceuticals industry which returned -6.6% over the past year.

CORT matched the United States of America Market (-0.4%) over the past year.


Share holder returns

CORTIndustryMarket
7 Day0.4%-1.8%-1.0%
30 Day18.1%-3.5%-3.3%
90 Day22.5%-3.8%0.8%
1 Year-0.4%-0.4%-4.3%-6.6%1.9%-0.4%
3 Year129.9%129.9%7.9%0.6%39.4%30.4%
5 Year362.3%362.3%22.9%10.0%54.2%37.1%

Price Volatility Vs. Market

How volatile is Corcept Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Corcept Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Corcept Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Corcept Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Corcept Therapeutics is overvalued based on earnings compared to the US Pharmaceuticals industry average.

Corcept Therapeutics is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Corcept Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

Corcept Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Corcept Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

-13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Corcept Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Corcept Therapeutics's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Corcept Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Corcept Therapeutics performed over the past 5 years?

69.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Corcept Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.

Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.


Return on Equity

Corcept Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Corcept Therapeutics used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Corcept Therapeutics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Corcept Therapeutics's financial position?


Financial Position Analysis

Corcept Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Corcept Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Corcept Therapeutics has no debt.

Corcept Therapeutics has no debt compared to 5 years ago when it was 1030.2%.

Corcept Therapeutics has no debt, it does not need to be covered by operating cash flow.

Corcept Therapeutics has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Corcept Therapeutics has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Corcept Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Corcept Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Corcept Therapeutics has not reported any payouts.

Unable to verify if Corcept Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Corcept Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Corcept Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Corcept Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Joseph Belanoff (62yo)

20.6yrs

Tenure

US$6,314,617

Compensation

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h ...


CEO Compensation Analysis

Joseph's remuneration is higher than average for companies of similar size in United States of America.

Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

3.3yrs

Average Tenure

57yo

Average Age

The tenure for the Corcept Therapeutics management team is about average.


Board Age and Tenure

20.6yrs

Average Tenure

65yo

Average Age

The average tenure for the Corcept Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$1,138,71014 Feb 19
George Baker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceUS$11.39
BuyUS$1,272,55026 Nov 18
George Baker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceUS$12.73
BuyUS$2,589,23014 Nov 18
George Baker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares200,000
Max PriceUS$13.00
BuyUS$461,09522 Aug 18
George Baker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares35,681
Max PriceUS$12.92

Ownership Breakdown


Management Team

  • Joseph Belanoff (62yo)

    Co-Founder

    • Tenure: 20.6yrs
    • Compensation: US$6.31m
  • Hazel Hunt

    Senior Vice President of Research

    • Tenure: 2.4yrs
  • Chris James

    Director of Investor Relations

    • Tenure: 0.0yrs
  • Charlie Robb (56yo)

    CFO & Secretary

    • Tenure: 7.9yrs
    • Compensation: US$2.85m
  • Don Laferle

    Senior Vice President

    • Tenure: 0.0yrs
  • Sean Maduck (42yo)

    Senior Vice President of Commercial

    • Tenure: 3.3yrs
    • Compensation: US$2.81m
  • Andreas Grauer (58yo)

    Chief Medical Officer

    • Tenure: 0.4yrs

Board Members

  • Len Baker (76yo)

    Director

    • Tenure: 20.6yrs
    • Compensation: US$267.89k
  • David Mahoney (65yo)

    Director

    • Tenure: 15.1yrs
    • Compensation: US$272.89k
  • Charles Nemeroff (69yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jim Wilson (75yo)

    Chairman

    • Tenure: 20.6yrs
    • Compensation: US$758.67k
  • Dan Swisher (56yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$280.26k
  • Joseph Belanoff (62yo)

    Co-Founder

    • Tenure: 20.6yrs
    • Compensation: US$6.31m
  • Florian Holsboer

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Bruce McEwen

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Ned Kalin

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • K. Ranga Krishnan (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs

Company Information

Corcept Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Corcept Therapeutics Incorporated
  • Ticker: CORT
  • Exchange: NasdaqCM
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.477b
  • Shares outstanding: 113.69m
  • Website: https://www.corcept.com

Number of Employees


Location

  • Corcept Therapeutics Incorporated
  • 149 Commonwealth Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CORTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2004
HTDDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2004
0I3QLSE (London Stock Exchange)YesCommon StockGBUSDApr 2004

Biography

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym ( ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:01
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.